Alnylam reports positive Phase 1b Huntington’s data for brezosiran
Alnylam Pharmaceuticals reported initial Phase 1b results for brezosiran in Huntington’s disease on October 23. At month 3, the highest evaluated dose produced a 60-64% mean reduction in cerebrospinal-fluid mutant huntingtin, with a maximum individual reduction of 83%. Alnylam plans a placebo-controlled pivotal study in 2027, subject to regulatory alignment, while reporting encouraging safety and tolerability data.
Why it matters
The results provide early clinical evidence of brezosiran’s mutant-huntingtin-lowering activity and support Alnylam’s plan to advance the program. The next major development is the planned pivotal study in 2027, which remains contingent on regulatory alignment.
Key facts
- 1The highest evaluated dose produced a 60-64% mean reduction in cerebrospinal-fluid mutant huntingtin at month 3, with a maximum individual reduction of 83%. investors.alnylam.com
- 2The initial data included participants followed for up to 12 months, with no dose-dependent increases in cerebrospinal-fluid inflammatory markers, neurofilament light chain or brain ventricular volume. investors.alnylam.com
- 3The Phase 1b study had 48 enrolled participants across five single-dose cohorts, while an additional Dose 6 cohort with N=12 was still enrolling and had not been evaluated. investors.alnylam.com
- 4Alnylam plans to start a placebo-controlled pivotal study in 2027, pending regulatory alignment. investors.alnylam.com
- 5Brezosiran is being developed by Alnylam in collaboration with Regeneron Pharmaceuticals. investors.alnylam.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.